News ICER says GLP-1s 'still have serious affordability issues' Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.
News NHS trust league tables arrive in UK health shakeup League tables for NHS trusts will end the postcode lottery of care, says the government, but not all are convinced.
News FDA lends a hand to Novo, Lilly on illegal GLP-1 imports The FDA has set up a green list of overseas sources for GLP-1 ingredients to try to block imports of illegitimate and potentially unsafe materials.
News Massachusetts bucks HHS, issuing its own COVID guidelines The Bay State is the first to require insurers to cover the shot for everyone, despite conflicting guidance from RFK's HHS on who should get the jab.
News FDA releases previously unseen CRLs in transparency push The FDA's earlier decision to publish complete response letters was largely a repackaging of existing information, but now it has gone much further.
News RFK faces bipartisan pressure at fractious hearing In a three-hour hearing before the Finance Committee, Senators took RFK to task about CDC ousting and broken promises about the COVID-19 vaccine.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face